The National Retina Institute Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2005
NCT00395707
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2005

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

ranibizumab (lucentis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1